Q1 2026 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Cut by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Zacks Research decreased their Q1 2026 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $2.01 per share for the quarter, down from their previous estimate of $2.09. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm’s revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.24) earnings per share.

A number of other brokerages have also recently commented on SRPT. Citigroup increased their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Evercore ISI raised their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research note on Tuesday, February 20th. Cantor Fitzgerald restated a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Mizuho raised their target price on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Finally, Needham & Company LLC cut their target price on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Stock Up 0.1 %

Sarepta Therapeutics stock opened at $117.12 on Wednesday. The company has a market cap of $11.00 billion, a P/E ratio of -19.14 and a beta of 0.94. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a fifty day simple moving average of $126.18 and a 200 day simple moving average of $110.21. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $159.89.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock valued at $2,739,419 in the last ninety days. 7.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the last quarter. Vanguard Capital Wealth Advisors grew its holdings in shares of Sarepta Therapeutics by 3.8% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 90 shares during the last quarter. DMC Group LLC grew its holdings in shares of Sarepta Therapeutics by 2.9% during the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 93 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the last quarter. Finally, Natixis Advisors L.P. grew its holdings in shares of Sarepta Therapeutics by 0.6% during the 3rd quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company’s stock valued at $3,155,000 after purchasing an additional 160 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.